## Michael Bergman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8420896/publications.pdf

Version: 2024-02-01

71 2,075 24
papers citations h-index

76 76 76 2155
all docs docs citations times ranked citing authors

44

g-index

#	Article	IF	CITATIONS
1	Bone mineral density, osteopenia and osteoporosis among US adults with cancer. QJM - Monthly Journal of the Association of Physicians, 2022, 115, 653-660.	0.5	5
2	Soluble Receptor for Advanced Glycation End Products (sRAGE) Isoforms Predict Changes in Resting Energy Expenditure in Adults with Obesity during Weight Loss. Current Developments in Nutrition, 2022, 6, nzac046.	0.3	5
3	Remission of T2DM requires early diagnosis and substantial weight reduction. Nature Reviews Endocrinology, 2022, 18, 329-330.	9.6	4
4	Continuous glucose monitoring and 1-h plasma glucose identifies glycemic variability and dysglycemia in high-risk individuals with HbA1c < 5.7%: a pilot study. Endocrine, 2022, 77, 403-407.	2.3	1
5	One-hour post-load glucose is associated with severity of hepatic fibrosis risk. Diabetes Research and Clinical Practice, 2022, 189, 109977.	2.8	9
6	Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. Diabetes Research and Clinical Practice, 2022, 190, 109980.	2.8	20
7	Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. Diabetes Care, 2021, 44, 1062-1069.	8.6	25
8	The 1-Hour Plasma Glucose: Common Link Across the Glycemic Spectrum. Frontiers in Endocrinology, 2021, 12, 752329.	3 <b>.</b> 5	8
9	Challenges of conducting a remote behavioral weight loss study: Lessons learned and a practical guide. Contemporary Clinical Trials, 2021, 108, 106522.	1.8	4
10	<p>The Oral Glucose Tolerance Test: 100 Years Later</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 3787-3805.	2.4	58
11	Dépistage précoce du prédiabèteÂ: y a-t-il une place pour une mesure de la glycémie à la 60eÂminute da test de surcharge orale en glucoseÂ?. Medecine Des Maladies Metaboliques, 2020, 14, 639-644.	'un 0.1	0
12	The Characteristics and Mortality of Osteoporosis, Osteomyelitis, or Rheumatoid Arthritis in the Diabetes Population: A Retrospective Study. International Journal of Endocrinology, 2020, 2020, 1-13.	1.5	3
13	Manhattan Veterans Affairs Medical Center Diabetes Prevention Clinic. Clinical Diabetes, 2020, 38, 291-294.	2.2	2
14	The OGTT is highly reproducible in Africans for the diagnosis of diabetes: Implications for treatment and protocol design. Diabetes Research and Clinical Practice, 2020, 170, 108523.	2.8	8
15	Nexus of COVID-19 and diabetes pandemics: Global public health lessons. Diabetes Research and Clinical Practice, 2020, 164, 108215.	2.8	13
16	Pitfalls of HbA1c in the Diagnosis of Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2803-2811.	3.6	11
17	Review of methods for detecting glycemic disorders. Diabetes Research and Clinical Practice, 2020, 165, 108233.	2.8	108
18	The contribution of unrecognized factors to the diabetes epidemic. Diabetes/Metabolism Research and Reviews, 2020, 36, e3315.	4.0	3

#	Article	IF	CITATIONS
19	Metabolic characteristics of Africans with normal glucose tolerance and elevated 1-hour glucose: insight from the Africans in America study. BMJ Open Diabetes Research and Care, 2020, 8, e000837.	2.8	5
20	Expanding Diabetes Prevention: Obstacles and Potential Solutions. American Journal of Preventive Medicine, 2019, 57, 853-857.	3.0	3
21	The rationale and design of the personal diet study, a randomized clinical trial evaluating a personalized approach to weight loss in individuals with pre-diabetes and early-stage type 2 diabetes. Contemporary Clinical Trials, 2019, 79, 80-88.	1.8	18
22	1-Hour Post-OGTT Glucose Improves the Early Prediction of Type 2 Diabetes by Clinical and Metabolic Markers. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1131-1140.	3.6	53
23	Reuniting overnutrition and undernutrition, macronutrients, and micronutrients.  Diabetes/Metabolism Research and Reviews, 2019, 35, e3072.	4.0	19
24	Lessons learned from the 1â€hour postâ€load glucose level during OGTT: Current screening recommendations for dysglycaemia should be revised. Diabetes/Metabolism Research and Reviews, 2018, 34, e2992.	4.0	38
25	Can insulin response patterns predict metabolic disease risk in individuals with normal glucose tolerance? Reply to Crofts CAP, Brookler K, Henderson G [letter]. Diabetologia, 2018, 61, 1234-1235.	6.3	0
26	The 1-h post-load plasma glucose as a novel biomarker for diagnosing dysglycemia. Acta Diabetologica, 2018, 55, 519-529.	2.5	31
27	Glucose patterns during an oral glucose tolerance test and associations with future diabetes, cardiovascular disease and all-cause mortality rate. Diabetologia, 2018, 61, 101-107.	6.3	43
28	Enhanced Predictive Capability of a 1-Hour Oral Glucose Tolerance Test: A Prospective Population-Based Cohort Study. Diabetes Care, 2018, 41, 171-177.	8.6	88
29	Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose†≥†155†mg/dl (8.6†mmol/L). Diabetes Research and Clinical Practice, 2018, 146, 18-33.	2.8	71
30	Reducing the prevalence of dysglycemia: is the time ripe to test the effectiveness of intervention in high-risk individuals with elevated 1 h post-load glucose levels? Endocrine, 2017, 55, 697-701.	2.3	10
31	Use of 1â€h postâ€load plasma glucose concentration to identify individuals at high risk of developing Type 2 diabetes. Diabetic Medicine, 2017, 34, 877-878.	2.3	11
32	Bariatric surgery, glycaemic status, and microvascular complications. Lancet Diabetes and Endocrinology,the, 2017, 5, 415.	11.4	0
33	An elevated 1-h post- load glucose level during the oral glucose tolerance test detects prediabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, 137-139.	3.6	7
34	Novel biomarkers for prediabetes, diabetes, and associated complications. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 345-361.	2.4	136
35	Oneâ€hour postâ€load plasma glucose level during the <scp>OGTT</scp> predicts mortality: observations from the Israel Study of Glucose Intolerance, Obesity and Hypertension. Diabetic Medicine, 2016, 33, 1060-1066.	2.3	54
36	One-hour post-load plasma glucose level during the OGTT predicts dysglycemia. Diabetes Research and Clinical Practice, 2016, 120, 221-228.	2.8	49

#	Article	IF	Citations
37	Baseline level of 30â€min plasma glucose is an independent predictor of incident diabetes among Asian Indians: analysis of two diabetes prevention programmes. Diabetes/Metabolism Research and Reviews, 2016, 32, 762-767.	4.0	12
38	Diabetes as a model for the disparate public response to acute versus chronic diseases. Endocrine, 2016, 51, 413-416.	2.3	1
39	Elevated 1-hour plasma glucose levels are associated with dysglycemia, impaired beta-cell function, and insulin sensitivity: a pilot study from a real world health care setting. Endocrine, 2016, 52, 172-175.	2.3	49
40	The 1-hour post-load glucose level is more effective than HbA1c for screening dysglycemia. Acta Diabetologica, 2016, 53, 543-550.	2.5	44
41	Editorial (Thematic Issue: Controversies and Current Approaches in the Diagnosis of Prediabetes and) Tj ETQq1 1	0.7.84314	ł rgBT /Overl
42	Definitions (and Current Controversies) of Diabetes and Prediabetes. Current Diabetes Reviews, 2015, 12, 8-13.	1.3	47
43	Dysglycemia and longâ€ŧerm mortality: observations from the Israel study of glucose intolerance, obesity and hypertension. Diabetes/Metabolism Research and Reviews, 2015, 31, 368-375.	4.0	19
44	Prediabetes and associated disorders. Endocrine, 2015, 48, 371-393.	2.3	111
45	The Early Diabetes Intervention Program – is <i>early</i> actually <i>late</i> ?. Diabetes/Metabolism Research and Reviews, 2014, 30, 654-658.	4.0	14
46	Diagnosis and Definition. , 2014, , 1-16.		0
47	Inadequacies of current approaches to prediabetes and diabetes prevention. Endocrine, 2013, 44, 623-633.	2.3	21
48	Are current diagnostic guidelines delaying early detection of dysglycemic states? Time for new approaches. Endocrine, 2013, 44, 66-69.	2.3	21
49	Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine, 2013, 43, 504-513.	2.3	89
50	The metabolic deterioration that antedates diabetes: personal trajectories of HbA <sub>1c</sub> and fasting glucose as early indicators and possible triggers for intervention. Diabetes/Metabolism Research and Reviews, 2013, 29, 1-7.	4.0	10
51	Diabetes prevention: global health policy and perspectives from the ground. Diabetes Management, 2012, 2, 309-321.	0.5	54
52	Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes. Acta Clinica Belgica, 2012, 67, 411-5.	1.2	6
53	Preface. Medical Clinics of North America, 2011, 95, xi-xiii.	2.5	3
54	Definition of Prediabetes. Medical Clinics of North America, 2011, 95, 289-297.	2.5	119

#	Article	IF	Citations
55	Inadequacies of absolute threshold levels for diagnosing prediabetes. Diabetes/Metabolism Research and Reviews, 2010, 26, 3-6.	4.0	40
56	Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. American Journal of Medicine, 1993, 94, 13-20.	1.5	169
57	Understanding the diabetic patient from a psychological dimension: Implications for the patient and the provider. American Journal of Psychoanalysis, 1990, 50, 25-33.	0.4	0
58	Abnormal ambient glucose levels inhibit proteoglycan core protein gene expression and reduce proteoglycan accumulation during chondrogenesis: possible mechanism for teratogenic effects of maternal diabetes Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 10113-10117.	7.1	31
59	Psychologic issues in diabetes care. American Family Physician, 1988, 37, 151-7.	0.1	O
60	High-density lipoprotein subclasses in diabetes. American Journal of Medicine, 1986, 81, 488-492.	1.5	24
61	The incidence of gestational hypoglycemia in insulin-dependent and non-insulin-dependent diabetic women. New York State Journal of Medicine, 1986, 86, 174-7.	0.1	5
62	The effect of glipizide on HDL and HDL subclasses. Diabetes Research, 1986, 3, 245-8.	0.1	4
63	Self-Monitoring of Blood Glucose in Diabetics Treated With Intraperitoneal Insulin-Reply. Archives of Internal Medicine, 1985, 145, 2128.	3.8	0
64	Insulin Pump Therapy Improves Blood Glucose Control During Hyperalimentation. Archives of Internal Medicine, 1984, 144, 2013.	3.8	6
65	Self-Monitoring of Blood Glucose Levels in Diabetes. Archives of Internal Medicine, 1984, 144, 2029.	3.8	17
66	Insulin pump therapy improves blood glucose control during hyperalimentation. Archives of Internal Medicine, 1984, 144, 2013-2015.	3.8	5
67	Nephrotic syndrome and immune complex glomerulonephritis associated with chlorpropamide therapy. American Journal of Medicine, 1983, 74, 337-342.	1.5	11
68	Newer approaches to the control of the insulin-dependent diabetic patient. Disease-a-Month, 1983, 29, 1-58.	1.1	8
69	Intensive Ambulatory Treatment of Insulin-Dependent Diabetes. Annals of Internal Medicine, 1982, 97, 225.	3.9	28
70	Insulin pump treatment for diabetes: unanswered questions. Clinical Physiology, 1982, 2, 263-268.	0.7	6
71	Insulin-Infusion-Pump Treatment of Diabetes. New England Journal of Medicine, 1981, 305, 303-307.	27.0	175